A new survey found that U.S. pharma marketers prefer using social media and mobile apps to reach healthcare providers.
Most physicians said EHRs have negatively impacted their communication with a patients.
A tracking poll conducted by the Kaiser Family Foundation also found that fewer Americans are seeing prescription drug ads compared to last year.
A new government investigation found that most but not all prices for generic drugs dispensed by Medicare Part D fell from 2010 to 2015.
Physicians are seeking beyond-the-pill services from drugmakers, but few sales reps shares details with docs about these programs, a new report finds.
IBM to help analyze data about the spread of Zika; Grassley to investigate Part D program; Lilly CEO to retire
Spending on CME rose in 2015; the FDA approves Valeant's Relistor; the Justice Department aims to block insurer merger
A new analysis suggests that $20 industry-sponsored meals may sway docs' prescribing habits.
The ability to pair data with a story or a human emotion is often easier for women.
Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.
Only 55% of the surveyed pharmaceutical executives said they are adopting digital as a key strategy in R&D.
BIO report finds success rate in Phase-I is 10%; Dunsire departs Forum after failed trials; the FDA issues two warning letters
Two recent polls paint a complicated picture of the public's opinion of the pharma industry.
Keytruda's survival benefit is reinforced by new study; drugmakers reference patient-assistance programs in debate over drug prices; China cuts drug prices
A 69% majority of healthcare organizations said they believe their industry is more vulnerable to data breaches than other business sectors.
2015 marks the second straight double digit increase in spend, which was driven by recent launches and specialty brands.
Analyst survey says docs want outcomes benefit from PCSK9s; Allergan licenses early-stage Alzheimer's drugs; Pfizer and IBM partner in Parkinson's disease
The results of a failed trial for Lilly's CEPT inhibitor has analysts saying there is little hope for Merck's drug in the same class.
Given the value of its data and its relatively backward security measures, the healthcare industry has become a prime target for hackers. But industry experts say changes are afoot.
Consumers are more likely to use health information websites they find easier to navigate than those perceived as trustworthy, like government sites, new research shows.
Analysis questions Addyi's effectiveness; Horizon is subpoenaed about its patient assistance programs; AstraZeneca sells non-U.S. rights to constipation drug
Healthcare spending rose in 2014; Publicis reorganizes its agency network; proposed New Jersey bill would punish drugmakers that move abroad
Healthcare may seem to have been unscarred by the ongoing rash of high-profile cyber-attacks, at least compared with retail and financial organizations. But to hear security pros tell it, the industry is increasingly finding itself as much of a target as companies in other sectors—if not more of one. Karen Epper Hoffman surveys the potential damage
Specialty medicines will keep drug spend trending upward through the next five years.
A pair of surveys paint a complicated picture of what direction pharma access to healthcare providers is going.
The public said drugmakers spend too much money on marketing to doctors and patients
Initiatives in Europe follow the US example when it comes to requiring manufacturers to report information about financial relationships with physicians.
An analysis of R&D data from 14 large drugmakers found that pharma is having renewed success in bringing medicines to market.
Report finds Americans overpay for cancer drugs; Clinton proposes end to pharma DTC as a tax write-off; Gilead HCV combo is effective across all strains of the virus
Accenture found that life-sciences executives believe that smart tools and devices will be the catalyst for drugmakers to move forward with beyond-the-pill initiatives.
As the value proposition of real-world data to drugmakers becomes increasingly attractive, services companies are partnering to capitalize on the opportunity.
Cardiologists say that up to 15% of their patients could be on PCSK9 inhibitors next year; FDA committee to evaluate new Oxycodone version
Sales reps that focus on creating value for HCPs could find new opportunities and improved access to those physicians, according to Accenture.
A new poll conducted by the Kaiser Family Foundation found that most Americans believe drugmakers should be required to release information to the public about how they set drug prices.
Less than half of 300 doctors polled in a QuantiaMD survey could name a biosimilar that's under consideration for approval, and only 17% said they're very likely to prescribe one.
A data-mining analysis of patient records found a significant increase in the chance of heart attack for those taking proton-pump inhibitors.
The American Academy of Otolaryngology said taking antibiotics for sinus infections is a slightly better treatment strategy than waiting it out.
A new survey from Cegedim Relationship Management claims that digital tools are being underutilized and represent an opportunity to meet the demands of HCPs.
A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.
Members of the 13-32 age group were less likely to agree that preventive care is the most important factor in staying healthy, compared to Baby Boomers and Gen-Xers.
As patients spend more time in waiting rooms where they are primed to learn about their health, POC promotions are becoming a more essential part of the marketing mix, researchers find.
Complementary solutions to drive growth with health plans as well as pharma clients, companies say.
Despite hurdles of practitioner buy-in and legacy IT, value-based care is on pace to overtake fee-for-service.
A mélange of new treatments awaiting approval and a lack of patient support are driving down drug utilization for Gilead's HCV blockbuster, according to a new study.